Pepaxto’s Accelerated Approval In Myeloma May Sink On OCEAN Trial's Adverse Survival Data

 
• By Sue Sutter
  
Ocean
Oncopeptides' melphalan flufenamide could be facing rough seas. • Source: Alamy

More from Review Pathways

More from Pathways & Standards